BioXcel Therapeutics is a company that makes medicines. They wanted to sell more of their shares (pieces of the company) to people, but they changed their minds because it was not a good time to do it. Now, they are going to work on something important with the FDA, which is like a big boss for medicines in America. This meeting will help them see if their new medicine works well at home for people who need it. Read from source...

- The headline is misleading and sensationalized, as it implies that the company's shares are rising only on Tuesday, when in fact they have been steadily increasing since last week.
- The article lacks any proper context or explanation for why the company decided to terminate its public offering, which could be an important factor for investors and potential buyers of the stock.
- The article fails to mention that BioXcel Therapeutics has already received breakthrough therapy designation from the FDA for its BXCL501 drug candidate, which is a significant achievement and a strong indicator of the drug's potential success in the market.
- The article also ignores the fact that BioXcel Therapeutics has a diverse pipeline of other drug candidates in various stages of development, which could provide additional revenue streams and growth opportunities for the company.
- The article uses vague and ambiguous terms such as "current market conditions" and "best interests of the stockholders", without providing any concrete evidence or analysis to support these claims.
- The article focuses too much on the upcoming FDA meeting, which is already priced into the stock and expected by most investors, rather than highlighting the company's long-term prospects, competitive advantages, or strategic partnerships.